Search results
Emcure Pharma Backed By Bain Capital Mobilises ₹583 Crore From Anchor Investors
Free Press Journal· 1 day agoBain Capital-backed Emcure Pharmaceuticals on Tuesday said it has garnered Rs 583 crore from anchor...
Bain Capital-backed Emcure Pharma mobilises Rs 583 cr from anchor investors - ET HealthWorld |...
The Economic Times· 1 day agoEmcure Pharma: The pharma firm has decided to allot 57.8 lakh equity shares to 48 funds at Rs 1,008...
Global firms buy PB Fintech stakes from early backers - The Economic Times
The Economic Times· 1 day agoAmerican financial services major Capital Group, and asset management companies T Rowe Price,...
Global firms buy PB Fintech stakes from early backers
The Economic Times· 1 day agoAmerican financial services major Capital Group, and asset management companies T Rowe Price,...
Ahead of IPO, Bansal Wire Industries garners Rs 223 cr from anchor investors
The Economic Times· 2 days agoThe company has allocated 87.30 lakh shares to 18 funds at Rs 256 apiece, which is also the upper...
Bansal Wire Industries IPO: Delhi-based firm garners ₹223 crore from anchor investors | Stock Market...
Livemint· 2 days agoAccording to the exchange filing, the company allocated 87,30,468 equity shares to anchor investors...
Bain Capital-backed Emcure Pharma mobilises Rs 583 cr from anchor investors
The Economic Times· 2 days agoEmcure Pharmaceuticals has allocated 57.8 lakh equity shares to 48 funds at the upper end of the IPO...
Emcure Pharmaceuticals IPO: Bain Capital backed firm raises ₹582 crore from anchor investors ahead...
Livemint· 2 days agoAccording to the exchange filing, the company has allocated 57,79,850 shares to 48 anchor investors...
Emcure Pharmaceuticals raises Rs 583 crore from anchor investors ahead of IPO
CNBC Awaaz· 2 days agoEmcure Pharmaceuticals IPO | Marquee global investors including Abu Dhabi Investment Authority,...
Bansal Wire Industries mobilises over Rs 223 crore via anchor book, IPO opens on July 3
CNBC Awaaz· 2 days agoBansal Wire Industries IPO comprises solely a fresh issue with no offer-for-sale component.